2.02
-0.04 (-1.94%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Jyong Biotech Ltd. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | -0.50 |
|
Jyong Biotech Ltd is a science-driven biotechnology company based in Taiwan and is committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia (primarily Taiwan and mainland China). It has been dedicated to the research and development of new drugs with high safety and efficacy. It has been developing a series of drug candidates, including one core drug candidate at NDA stage, one clinical-stage key drug candidate and other preclinical-stage drug candidates. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 62.21% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| China Universal Asset Management Co., Ltd. | 30 Jun 2026 | 12,100 |
| State Of Wyoming | 30 Jun 2026 | 11,208 |
| Mirae Asset Global Investments Co., Ltd. | 30 Jun 2026 | 3,400 |
| Gf Fund Management Co. Ltd. | 30 Jun 2026 | 1,559 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |